<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>26705959</identifier>
<setSpec>1989-2284</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Bover, Jordi</dc:author>
<dc:author>Praga, Manuel</dc:author>
<dc:author>Torregrosa, José Vicente</dc:author>
<dc:author>Fernández-Giráldez, Elvira</dc:author>
<dc:author>Egido, Jesús</dc:author>
<dc:author>Solozábal, Carlos</dc:author>
<dc:author>Martínez-Castelao, Alberto</dc:author>
<dc:description xml:lang="en">Secondary hyperparathyroidism (SHPT) is a common complication in patients with chronic kidney disease (CKD) that is characterised by elevated parathyroid hormone (PTH) levels and a series of bone-mineral metabolism anomalies. In patients with SHPT, treatment with paricalcitol, a selective vitamin D receptor activator, has been shown to reduce PTH levels with minimal serum calcium and phosphorus variations. The classic effect of paricalcitol is that of a mediator in mineral and bone homeostasis. However, recent studies have suggested that the benefits of treatment with paricalcitol go beyond PTH reduction and, for instance, it has a positive effect on cardiovascular disease and survival. The objective of this study is to review the most significant studies on the so-called pleiotropic effects of paricalcitol treatment in patients with CKD.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>Trasplante</dc:subject>
<dc:subject>Hormona paratiroidea</dc:subject>
<dc:subject>Calcificación vascular</dc:subject>
<dc:subject>Secondary hyperparathyroidism</dc:subject>
<dc:subject>Vitamina D</dc:subject>
<dc:subject>Hiperparatiroidismo secundario</dc:subject>
<dc:subject>Transplant</dc:subject>
<dc:subject>Aterosclerosis</dc:subject>
<dc:subject>Vitamin D</dc:subject>
<dc:subject>Parathyroid hormone</dc:subject>
<dc:subject>Atherosclerosis</dc:subject>
<dc:subject>Diálisis</dc:subject>
<dc:subject>Vascular calcification</dc:subject>
<dc:subject>Dialysis</dc:subject>
<dc:subject>Proteinuria</dc:subject>
<dc:date>2016 </dc:date>
<dc:title xml:lang="en">The pleiotropic effects of paricalcitol: Beyond bone-mineral metabolism.</dc:title>
<dc:publisher>Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
